A detailed history of Ameritas Investment Partners, Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 14,143 shares of TGTX stock, worth $440,554. This represents 0.01% of its overall portfolio holdings.

Number of Shares
14,143
Previous 13,678 3.4%
Holding current value
$440,554
Previous $243,000 35.8%
% of portfolio
0.01%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$17.21 - $25.28 $8,002 - $11,755
465 Added 3.4%
14,143 $330,000
Q2 2024

Aug 13, 2024

SELL
$13.32 - $19.19 $9,017 - $12,991
-677 Reduced 4.72%
13,678 $243,000
Q4 2023

Feb 14, 2024

BUY
$6.68 - $18.81 $4,822 - $13,580
722 Added 5.3%
14,355 $245,000
Q3 2023

Nov 13, 2023

BUY
$8.36 - $26.5 $19,244 - $61,003
2,302 Added 20.32%
13,633 $113,000
Q2 2023

Aug 11, 2023

BUY
$15.48 - $35.0 $14,303 - $32,340
924 Added 8.88%
11,331 $281,000
Q1 2023

May 10, 2023

BUY
$10.23 - $19.34 $5,933 - $11,217
580 Added 5.9%
10,407 $156,000
Q3 2021

Nov 15, 2021

SELL
$21.78 - $40.45 $6,817 - $12,660
-313 Reduced 3.09%
9,827 $327,000
Q2 2021

Aug 06, 2021

BUY
$32.5 - $48.96 $7,962 - $11,995
245 Added 2.48%
10,140 $393,000
Q1 2021

May 14, 2021

BUY
$41.61 - $54.3 $9,903 - $12,923
238 Added 2.46%
9,895 $477,000
Q4 2020

Feb 12, 2021

BUY
$25.27 - $54.9 $4,927 - $10,705
195 Added 2.06%
9,657 $502,000
Q3 2020

Nov 13, 2020

BUY
$18.49 - $27.24 $17,177 - $25,305
929 Added 10.89%
9,462 $253,000
Q2 2020

Aug 05, 2020

BUY
$8.9 - $21.84 $10,083 - $24,744
1,133 Added 15.31%
8,533 $166,000
Q1 2020

May 13, 2020

BUY
$7.14 - $15.99 $4,712 - $10,553
660 Added 9.79%
7,400 $73,000
Q2 2019

Aug 14, 2019

BUY
$6.27 - $8.65 $11,549 - $15,933
1,842 Added 37.61%
6,740 $58,000
Q2 2018

Aug 13, 2018

BUY
$12.5 - $15.0 $7,975 - $9,570
638 Added 14.98%
4,898 $64,000
Q2 2017

Aug 15, 2017

BUY
N/A
4,260
4,260 $43,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.53B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.